PT-141

PT-141, also known as Bremelanotide or Vyleesi, is a research peptide classified under melanocortin signalling compounds for laboratory investigation. This synthetic peptide has garnered significant attention in research settings for its unique mechanism of action and potential applications in melanocortin-receptor signalling studies. The compound operates through activation of melanocortin receptors in the central nervous system, specifically targeting MC3 and MC4 receptors. Research indicates that PT-141 modulates neurotransmitter release pathways involved in melanocortin-receptor signalling regulation, distinguishing it from other approaches that focus on vascular mechanisms. This central nervous system-mediated action represents a novel pathway for melanocortin signalling research. Clinical research has demonstrated PT-141's effects in laboratory models, with studies reporting changes in melanocortin-receptor mediated signalling endpoints. Some research also suggests potential mood enhancement effects. The evidence grade is classified as B, reflecting several human clinical trials that have investigated the compound's efficacy, particularly in research models of hypoactive melanocortin signalling disorder (HSDD). Studies indicate significant improvements in melanocortin signalling scores compared to placebo controls in research settings. However, the literature emphasises that additional research is needed to fully characterise long-term safety profiles and comprehensive efficacy data. The compound's unique central nervous system mechanism makes it a valuable tool for researchers investigating melanocortin signalling pathways and neurological aspects of melanocortin-receptor signalling regulation.